이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

표피 성장 인자 수용체(EGFR)-돌연변이 비소세포폐암을 포함한 진행성 또는 전이성 고형 종양이 있는 참가자에서 아미반타맙에 대한 연구 (PALOMA-2)

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

EGFR 변이 비소세포폐암을 포함한 진행성 또는 전이성 고형 종양 환자의 다중 요법에서 피하 아미반타맙의 2상 공개 라벨 병렬 코호트 연구

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).

연구 개요

연구 유형

중재적

등록 (추정된)

520

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Goyang-si, 대한민국, 10408
        • 모병
        • National Cancer Center
      • Seongnam-si, 대한민국, 13620
        • 모병
        • Seoul National University Bundang Hospital
      • Seoul, 대한민국, 03080
        • 모병
        • Seoul National University Hospital
      • Seoul, 대한민국, 03722
        • 모병
        • Severance Hospital Yonsei University Health System
      • Seoul, 대한민국, 05505
        • 완전한
        • Asan Medical Center
      • Berlin, 독일, 13125
        • 완전한
        • Evangelische Lungenklinik Berlin
      • Cologne, 독일, 50937
        • 모병
        • Universitaetsklinikum Koeln
      • Grosshandorf, 독일, 22927
        • 모병
        • LungenClinic Grosshansdorf GmbH
      • Immenhausen, 독일, 34376
        • 모병
        • Lungenfachklinik Immenhausen
      • Würzburg, 독일, 97074
        • 모병
        • Klinikum Würzburg Mitte gGmbH Standort Missioklinik
      • Kuala Lumpur, 말레이시아, 59100
        • 모병
        • University Malaya Medical Centre
      • Kuantan, 말레이시아, 25100
        • 모병
        • Hospital Tengku Ampuan Afzan
      • Kuching, 말레이시아, 93586
        • 모병
        • Hospital Umum Sarawak
      • Petaling Jaya, 말레이시아, 46050
        • 모병
        • Beacon Hospital Sdn Bhd
    • California
      • La Jolla, California, 미국, 92093
        • 모병
        • University of California at San Diego
      • Orange, California, 미국, 92868
        • 모병
        • University of California Irvine
      • Stanford, California, 미국, 94305
        • 모병
        • Stanford Cancer Institute
    • District of Columbia
      • Washington D.C., District of Columbia, 미국, 20016
        • 모병
        • Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
    • Florida
      • Boca Raton, Florida, 미국, 33486
        • 완전한
        • Baptist Lynn Cancer Institute
      • Miami Beach, Florida, 미국, 33140
        • 모병
        • Mount Sinai Medical Center
      • Orlando, Florida, 미국, 32804
        • 모병
        • AdventHealth
      • Tampa, Florida, 미국, 33612
        • 완전한
        • H. Lee Moffitt Cancer & Research Institute
    • Kansas
      • Westwood, Kansas, 미국, 66205
        • 모병
        • University of Kansas Cancer Center
    • Maryland
      • Baltimore, Maryland, 미국, 21224
        • 모병
        • Sidney Kimmel Cancer Center - Bayview Campus
    • Massachusetts
      • Boston, Massachusetts, 미국, 02118
        • 모병
        • Boston Medical Center
    • Missouri
      • St Louis, Missouri, 미국, 63110
        • 모병
        • Washington University School Of Medicine
    • New Jersey
      • Hackensack, New Jersey, 미국, 07601
        • 모병
        • Hackensack University Medical Center
      • New Brunswick, New Jersey, 미국, 08901
        • 모병
        • Rutgers Cancer Institute of New Jersey
    • New York
      • East Syracuse, New York, 미국, 13057
        • 완전한
        • Hematology-Oncology Associates of CNY
    • North Carolina
      • Charlotte, North Carolina, 미국, 28204
        • 완전한
        • Novant Health 1
      • Winston-Salem, North Carolina, 미국, 27106
        • 완전한
        • Novant Health
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • 완전한
        • Cleveland Clinic
      • Cleveland, Ohio, 미국, 44111
        • 완전한
        • Cleveland Clinic 1
      • Mayfield Heights, Ohio, 미국, 44124
        • 완전한
        • Cleveland Clinic 2
      • Warrensville Heights, Ohio, 미국, 44122
        • 완전한
        • Cleveland Clinic 3
    • Utah
      • Salt Lake City, Utah, 미국, 84112
        • 완전한
        • The Huntsman Cancer Institute
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • 모병
        • Virginia Cancer Specialists
    • Washington
      • Everett, Washington, 미국, 98201
        • 완전한
        • Providence Regional Cancer Partnership
      • Seattle, Washington, 미국, 98104
        • 모병
        • Swedish Cancer Institute
      • Seattle, Washington, 미국, 98101
        • 완전한
        • Virginia Mason Medical Center
      • Barretos, 브라질, 14784-400
        • 모병
        • Fundacao Pio XII
      • Belo Horizonte, 브라질, 30130 090
        • 모병
        • PERSONAL Oncologia de Precisao e Personalizada
      • Londrina, 브라질, 86015 520
        • 모병
        • Hospital do Cancer de Londrina
      • Porto Alegre, 브라질, 90035-001
        • 모병
        • Hospital Moinhos de Vento
      • Rio de Janeiro, 브라질, 22281 100
        • 모병
        • IDOR - Regional Rio de Janeiro
      • Salvador, 브라질, 41253-190
        • 모병
        • IDOR - Regional Bahia
      • São Paulo, 브라질, 01509 900
        • 모병
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, 브라질, 01327 001
        • 모병
        • Hospital Alemao Oswaldo Cruz
      • São Paulo, 브라질, 01409-001
        • 완전한
        • Impar Servicos Hospitalares SA Hospital Nove de Julho
      • A Coruña, 스페인, 15006
        • 모병
        • Hosp Univ A Coruna
      • Alicante, 스페인, 03010
        • 모병
        • General University Hospital of Alicantet
      • Barcelona, 스페인, 08025
        • 모병
        • Hosp. de La Santa Creu I Sant Pau
      • Barcelona, 스페인, 08003
        • 모병
        • Hosp. Del Mar
      • Barcelona, 스페인, 8908
        • 모병
        • Inst. Cat. Doncologia-H Duran I Reynals
      • Barcelona, 스페인, 08035
        • 모병
        • Hosp Univ Vall D Hebron
      • Madrid, 스페인, 28034
        • 모병
        • Hosp. Univ. Ramon Y Cajal
      • Madrid, 스페인, 28041
        • 모병
        • Hosp. Univ. 12 de Octubre
      • Madrid, 스페인, 28046
        • 모병
        • Hosp. Univ. La Paz
      • Madrid, 스페인, 28007
        • 모병
        • Hosp. Gral. Univ. Gregorio Maranon
      • Málaga, 스페인, 29010
        • 모병
        • Hosp Regional Univ de Malaga
      • Seville, 스페인, 41009
        • 모병
        • Hosp. Virgen Macarena
      • Valencia, 스페인, 46010
        • 모병
        • Hosp. Clinico Univ. de Valencia
      • Valencia, 스페인, 46014
        • 모병
        • Hosp. Gral. Univ. Valencia
      • Cheltenham, 영국, GL53 7AN
        • 완전한
        • Cheltenham General Hospital
      • Devon, 영국, TQ2 7AA
        • 모병
        • Torbay Hospital-Devon
      • Edinburgh, 영국, EH4 2XU
        • 모병
        • Edinburgh Cancer Centre Western General
      • Leicester, 영국, LE1 5WW
        • 모병
        • Leicester Royal Infirmary
      • London, 영국, NW1 2PG
        • 모병
        • University College London Hospitals
      • Nottingham, 영국, NG5 1PB
        • 모병
        • Nottingham City Hospital
      • Portsmouth, 영국, PO6 3LY
        • 모병
        • Queen Alexandra Hospital
      • Haifa, 이스라엘, 3109601
        • 모병
        • Rambam Medical Center
      • Jerusalem, 이스라엘, 9103102
        • 모병
        • Shaare Zedek Medical Center
      • Kfar Saba, 이스라엘, 44281
        • 완전한
        • Meir Medical Center
      • Petah Tikva, 이스라엘, 4941492
        • 모병
        • Rabin Medical Center
      • Ramat Gan, 이스라엘, 52621
        • 모병
        • Sheba Medical Center
      • Genova, 이탈리아, 16132
        • 모병
        • Policlinico Hospital San Martino- IRCCS for Oncology
      • Milan, 이탈리아, 20132
        • 모병
        • Ospedale San Raffaele
      • Milan, 이탈리아, 20162
        • 모병
        • ASST Grande Ospedale Metropolitano Niguarda
      • Monza, 이탈리아, 20090
        • 모병
        • Azienda Ospedaliera San Gerardo
      • Naples, 이탈리아, 80131
        • 모병
        • Azienda Ospedaliera Specialistica dei Colli
      • Himeji, 일본, 670-8520
        • 모집하지 않고 적극적으로
        • National Hospital Organization Himeji Medical Center
      • Matsusaka, 일본, 515 8544
        • 모집하지 않고 적극적으로
        • Saiseikai Matsusaka Municipal Hospital
      • Niigata, 일본, 951-8566
        • 모집하지 않고 적극적으로
        • Niigata Cancer Center Hospital
      • Shizuoka, 일본, 411 8777
        • 모집하지 않고 적극적으로
        • Shizuoka Cancer Center
      • Tokyo, 일본, 135 8550
        • 모집하지 않고 적극적으로
        • The Cancer Institute Hospital of JFCR
      • Wakayama, 일본, 641 8510
        • 모집하지 않고 적극적으로
        • Wakayama Medical University Hospital
      • Baoding, 중국, 071051
        • 완전한
        • Affiliated Hospital of Hebei University
      • Changchun, 중국, 130000
        • 모병
        • Jilin cancer hospital
      • Chengdu, 중국, 610041
        • 모병
        • Sichuan Cancer Hospital
      • Chengdu, 중국, 610047
        • 모병
        • West China Hospital Sichuan University
      • Chongqing, 중국, 400038
        • 모병
        • The First Affiliated Hospital of PLA Army Medical University
      • Guangzhou, 중국, 510060
        • 모병
        • The First Affiliated Hospital Sun Yat sen University
      • Hangzhou, 중국, 310003
        • 모병
        • The First Affiliated Hospital Zhejiang University College of Medicine
      • Hangzhou, 중국, 310016
        • 모병
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Harbin, 중국, 150000
        • 모병
        • Harbin medical university cancer hospital
      • Huizhou, 중국, 516001
        • 모병
        • Huizhou Municipal Central Hospital
      • Liuzhou, 중국, 545006
        • 완전한
        • Liuzhou people's Hospital
      • Shanghai, 중국, 200032
        • 모병
        • Fudan University Shanghai Cancer Center
      • Tianjin, 중국, 300052
        • 모병
        • Tianjin Medical University General Hospital
      • Wenzhou, 중국, 325000
        • 모병
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, 중국, 430022
        • 모병
        • Union Hospital Tongji Medical College of Huazhong University of Science and Technology
      • Wuxi, 중국, 214122
        • 완전한
        • Hospital of Jiangnan University
      • Xi'an, 중국, 710061
        • 모병
        • The First Affiliated Hospital of Xian Jiaotong University
      • Yantai, 중국, 264000
        • 완전한
        • Yantai Yuhuangding Hospital
      • Caen, 프랑스, 14076
        • 모병
        • Centre Francois Baclesse
      • Dijon, 프랑스, 21079
        • 완전한
        • Centre Georges-François Leclerc
      • Nîmes, 프랑스, 30029
        • 모병
        • Institut de Cancérologie du Gard
      • Paris, 프랑스, 75248
        • 모병
        • Institut Curie
      • Saint-Herblain, 프랑스, 44805
        • 모병
        • Institut de cancerologie de l'ouest
      • Villejuif, 프랑스, 94800
        • 모병
        • Gustave Roussy

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-small cell lung cancer (NSCLC) that is not amenable to curative therapy including surgical resection or chemoradiation. Additional Cohort specific disease requirements include: Cohorts 1, 3, 3b, 5, 6 and 7: epidermal growth factor receptor (EGFR) exon 19 deletion (Exon19del) or Exon 21 L858R mutation; Cohort 2: EGFR Exon 20ins mutation. Cohorts 1,5,and6: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohort 2: Participant should not have received any prior systemic therapy for locally advanced or metastatic NSCLC. Cohorts 3and3b: Participant must have progressed on or after osimertinib monotherapy as the most recent line of treatment. Osimertinib must have been administered as either the first-line treatment for locally advanced or metastatic disease or in the second-line setting after prior treatment with first- or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy. Cohort 4: Participants need to currently be on an amivantamab IV Q2W regimen (1,050 mg or 1,400 mg depending on weight) for at least 8 weeks, as part of standard of care, an expanded access program, or as a rollover from a long-term extension, without any amivantamab dose reduction. Cohort 7: Participants must have progressed on or after the combination of amivantamab and lazertinib as the most recent line of treatment. The combination of amivantamab and lazertinib must have been administered as the first-line treatment for locally advanced or metastatic disease. Cohort 2, 3, 3b, and 7 only: Squamous NSCLC are excluded. EGFR mutation must have been identified as determined by Food and Drug Administration (FDA) approved or other validated test of either circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US). A copy of the initial test report documenting the EGFR mutation must be included in the participant records and a deidentified copy must also be submitted to the sponsor
  • All cohorts except Cohort 4: Participants must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. If the only target lesion has been previously irradiated, it must show signs of disease progression since radiation was completed If only 1 non-irradiated measurable lesion exists, which undergoes a biopsy and is acceptable as a target lesion, the baseline tumor assessment scans should be performed at least 14 days after the biopsy
  • May have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment(s)
  • Have adequate organ (renal, hepatic, hematological, coagulation and cardiac) functions
  • Participant must have eastern cooperative oncology group (ECOG) status of 0 or 1
  • Cohort 6: Must be eligible for, and agree to comply with, the use of prophylactic anticoagulation with a direct oral anticoagulant or a low molecular weight heparin during the first 4 months of study treatment
  • A participant must agree not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction during the study and for a period of 6 months after receiving the last dose of study treatment. Participants with child bearing potential should consider preservation of eggs prior to study treatment as anti-cancer treatments may impair fertility

Exclusion Criteria:

  • Participant has a medical history of interstitial lung disease (ILD), including drug induced ILD or radiation pneumonitis
  • Participant has a history of hypersensitivity to any excipients of the investigational products to be used in their enrollment cohort
  • Participant has received a live or live attenuated vaccine within 3 months before Cycle 1 Day 1. The seasonal influenza vaccine and non-live vaccines against Coronavirus disease 19 (COVID-19) are not exclusionary
  • For all cohorts (with regimens potentially including lazertinib): Participant is currently receiving medications or herbal supplements known to be potent Cytochrome (CYP3A4/5) inducers and is unable to stop use for an appropriate washout period prior to Cycle 1 Day 1
  • Other clinically active liver disease of infectious origin
  • Participant has a history of clinically significant cardiovascular disease including, but not limited to: a) All cohorts: diagnosis of deep vein thrombosis or pulmonary embolism within 1 month prior to the first dose of study treatment(s), or any of the following within 6 months prior to the first dose of study treatment(s): myocardial infarction, unstable angina, stroke, transient ischemic attack, coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinically non-significant thrombosis, such as non-obstructive catheter-associated clots, are not exclusionary; b) All cohorts (with regimens potentially including lazertinib): Participant has a significant genetic predisposition to venous thromboembolic events (VTE; such as Factor V Leiden); c) All cohorts (with regimens potentially including lazertinib): Participant has a prior history of VTE and is not on appropriate therapeutic anticoagulation as per NCCN or local guidelines; d) prolonged corrected QT interval by Fridericia (QTcF) interval greater than (>) 480 milliseconds (msec) or clinically significant cardiac arrhythmia or electrophysiologic disease (example, placement of implantable cardioverter defibrillator or atrial fibrillation with uncontrolled rate); e) uncontrolled (persistent) hypertension: systolic blood pressure >160 millimeter(s) of mercury (mmHg); diastolic blood pressure >100 mmHg; f) Congestive heart failure defined as NYHA class III-IV or hospitalization for congestive heart failure (CHF) (any New York Heart Association [NYHA] class) within 6 months of treatment initiation at Cycle 1/day 1 (C1D1); g) pericarditis/clinically significant pericardial effusion; h) myocarditis; i) baseline left ventricular ejection fraction (LVEF) below the institution's lower limit of normal at screening, as assessed by echocardiogram or multigated acquisition (MUGA) scan
  • Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants who have received definitive radiation or surgical treatment for symptomatic or unstable brain metastases and have been clinically stable and asymptomatic for at least 2 weeks before Screening are eligible, provided they have been either off corticosteroid treatment or are receiving low-dose corticosteroid treatment (less than or equal to [<=] 10 milligrams per day [mg/day] prednisone or equivalent) for at least 2 weeks prior to treatment allocation

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort 1(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q2W) + Lazertinib

Participants with treatment-naive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an epidermal growth factor receptor (EGFR) exon 19 deletion (exon19del) or exon 21 leucine 858 to arginine substitution (exon 21 L858R) mutation, will receive amivantamab SC-CF injection, 1600 milligrams (mg) or 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily. Eligible participants will be given an option to enter long-term extension (LTE) phase and may continue to receive access to study treatment(s) within the study by transferring to the Drug Access (DA)-LTE Phase.

Amivantamab will be administered subcutaneously by manual injection.

다른 이름들:
  • JNJ-61186372

Lazertinib will be administered as an oral tablet.

다른 이름들:
  • JNJ-73841937; YH25448
실험적: Cohort 2(Exon20 NSCLC,1L, Previously Untreated): Amivantamab (Q3W) + Chemotherapy

Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR exon20ins mutation will receive Amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle, starting with Cycle 2 along with pemetrexed 500 milligrams per meter square (mg/m^2) as intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and IV infusion carboplatin area under the concentration-time curve 5 milligrams per milliliters (mg/mL) per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase.

Amivantamab will be administered subcutaneously by manual injection.

다른 이름들:
  • JNJ-61186372

Carboplatin will be administrated by IV infusion.

Pemetrexed will be administered by IV infusion.

실험적: Cohort 3(Exon19del/Exon21 L858R NSCLC,2L,Post Osimertinib):Amivantamab(Q3W)+Lazertinib+Chemotherapy

Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Lazertinib 240 mg orally once daily starting Cycle 5 Day 1 when carboplatin is complete or sooner if carboplatin discontinued earlier than Cycle 4. Eligible participants will be given an option to enter LTE phase and DA-LTE Phase.

Amivantamab will be administered subcutaneously by manual injection.

다른 이름들:
  • JNJ-61186372

Lazertinib will be administered as an oral tablet.

다른 이름들:
  • JNJ-73841937; YH25448

Carboplatin will be administrated by IV infusion.

Pemetrexed will be administered by IV infusion.

실험적: Cohort 3b(Exon19del/Exon21 L858R NSCLC, 2L, Post Osimertinib): Amivantamab (Q3W)+Chemotherapy

Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after treatment with a third-generation EGFR TKI (osimertinib), will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase.

Amivantamab will be administered subcutaneously by manual injection.

다른 이름들:
  • JNJ-61186372

Carboplatin will be administrated by IV infusion.

Pemetrexed will be administered by IV infusion.

실험적: Cohort 4(Previously Treated with Amivantamab IV): Switch from Amivantamab IV to SC-CF (Q2W)

Participants who were previously on amivantamab IV once every 2 weeks (Q2W) regimen as part of standard of care, for at least 8 weeks, either as monotherapy or combination with lazertinib, will receive amivantamab SC-CF injection 1600 mg and 2240 mg if body weight is greater than or equal to 80 kg. Participants who continue to benefit from study treatments, as determined by their investigator, may shift to the drug access (DA)-LTE phase.

Amivantamab will be administered subcutaneously by manual injection.

다른 이름들:
  • JNJ-61186372

Lazertinib will be administered as an oral tablet.

다른 이름들:
  • JNJ-73841937; YH25448
실험적: Cohort 5(Exon19del/Exon21 L858R NSCLC, 1L, Previously Untreated): Amivantamab (Q4W) + Lazertinib

Participants with treatment-naïve locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation will receive amivantamab SC-CF induction with 1,600 mg (or 2,240 mg if BW >=80 kg) on Cycle 1 Days 1, 8, 15, and 22, starting with Cycle 2 on Day 1 of each next 28-day cycle, amivantamab SC-CF (160 mg/mL co-formulated with rHuPH20) by manual injection at 3,520 mg (or 4,640 mg if BW >=80 kg); along with lazertinib 240 mg by mouth once daily from Cycle 1 Day 1. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase.

Amivantamab will be administered subcutaneously by manual injection.

다른 이름들:
  • JNJ-61186372

Lazertinib will be administered as an oral tablet.

다른 이름들:
  • JNJ-73841937; YH25448
실험적: Cohort6(Exon19del/Exon21L858R,NSCLC1L,PreviouslyUntreated):Amivantamab(Q2W)+Lazertinib+Anticoagulant

Participants with treatment-naive locally advanced or metastatic NSCLC harboring an EGFR Exon19del or Exon 21 L858R mutation treated will receive will receive amivantamab SC-CF injection, 1600 milligrams (mg) and 2240 mg if body weight is greater than or equal to (>=) 80 kilograms (kg), on Cycle 1 Days 1, 8, 15, and 22 and on Days 1 and 15 of each subsequent 28-day cycle, starting with Cycle 2, along with lazertinib 240 mg orally once daily from Cycle 1 Day 1. Participants will additionally take prophylactic anticoagulation with a direct oral anticoagulant (DOAC) or a low molecular weight heparin (LMWH) for the first four months of study treatment (from Day 1 through Day 120) with the combination of amivantamab and lazertinib. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase.

Amivantamab will be administered subcutaneously by manual injection.

다른 이름들:
  • JNJ-61186372

Lazertinib will be administered as an oral tablet.

다른 이름들:
  • JNJ-73841937; YH25448

DOAC will be administered orally.

LMWH will be administered subcutaneously.

실험적: Cohort 7(Exon19del/Exon21 L858R NSCLC,2L,Post Amivantamab+Lazertinib):Amivantamab(Q3W)+Chemotherapy

Participants with locally advanced or metastatic NSCLC harboring an EGFR exon19del or exon 21 L858R mutation who have experienced disease progression on or after the combination of amivantamab and lazertinib will receive amivantamab SC-CF injection 1600 mg or 2240 mg if body weight is >=80 kg on Cycle 1 Day 1, 2400 mg or 3360 mg if body weight is >=80 kg on Cycle 1 Day 8 and 15 and on Day 1 of each subsequent 21-day cycle starting with Cycle 2; in combination with IV infusion carboplatin area under the concentration-time curve 5 mg/mL per minute (AUC 5) maximum 750 mg on Day 1 of each 21-day cycle, for up to 4 cycles; and pemetrexed 500 mg/m^2 as an IV infusion (with vitamin supplementation) on Day 1 of each 21-day until disease progression. Eligible participants will be given an option to enter LTE phase and may continue to receive access to study treatment(s) within the study by transferring to the DA-LTE Phase.

Amivantamab will be administered subcutaneously by manual injection.

다른 이름들:
  • JNJ-61186372

Carboplatin will be administrated by IV infusion.

Pemetrexed will be administered by IV infusion.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
All Cohorts Except Cohort 4: Objective Response Rate (ORR) Based on Investigator Assessment (INV)
기간: Up to 1 year 6 months

ORR based on INV will be reported. ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as determined by investigator.

Up to 1 year 6 months
Cohort 4: Number of Participants with Adverse Events (AEs)
기간: Up to approximately 4 years and 9 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.

Up to approximately 4 years and 9 months
Cohort 4: Number of Participants with AEs by Severity
기간: Up to approximately 4 years and 9 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to approximately 4 years and 9 months
Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values
기간: Up to approximately 4 years and 9 months

Number of participants with abnormalities in clinical laboratory values (which includes serum chemistry, hematology, coagulation, urinalysis, and serology) will be reported.

Up to approximately 4 years and 9 months
Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity
기간: Up to approximately 4 years and 9 months

Number of participants with laboratory values abnormalities which includes serum chemistry, hematology, coagulation, urinalysis, and serology) by severity will be reported. Severity of laboratory values abnormalities will be graded according to the NCI-CTCAE version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to approximately 4 years and 9 months

2차 결과 측정

결과 측정
측정값 설명
기간
All Cohorts Except Cohort 4: Number of Participants with AEs
기간: Up to 1 year 6 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.

Up to 1 year 6 months
All Cohorts Except Cohort 4: Number of Participants with AEs by Severity
기간: Up to 1 year 6 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to 1 year 6 months
All Cohorts Except Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values
기간: Up to 1 year 6 months

Number of participants with abnormalities in clinical laboratory values (which includes serum chemistry, hematology, coagulation, urinalysis, and serology) will be reported.

Up to 1 year 6 months
All Cohorts Except Cohort 4: Number of Participants with Abnormalities in Clinical Laboratory Values by Severity
기간: Up to 1 year 6 months

Number of participants with abnormalities in clinical laboratory values which includes serum chemistry, hematology, coagulation, urinalysis, and serology) by severity will be reported. Severity of laboratory values abnormalities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to 1 year 6 months
All Cohorts Except Cohort 4: ORR Based on Independent Central Review (ICR)
기간: Up to 1 year 6 months

ORR based on ICR will be reported. The ORR is defined as the percentage of participants who achieve a CR or PR, based on RECIST version 1.1, as confirmed by ICR.

Up to 1 year 6 months
All Cohorts Except Cohort 4: Duration of Response (DoR) Based on Investigator Assessment (INV)
기간: Up to 1 year 6 months

DoR based on INV is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever comes first, for participants who have PR or CR.

Up to 1 year 6 months
All Cohorts Except Cohort 4: Time to Response (TTR) Based on INV
기간: Up to 1 year 6 months

TTR (that is, time to first response) based on INV is defined as the time from the first dose of study treatment to the date of first documentation of a response (PR or CR) prior to any disease progression and subsequent anticancer therapy, based on RECIST version 1.1., for participants who have PR or CR as their best response.

Up to 1 year 6 months
All Cohorts Except Cohort 4: Clinical Benefit Rate (CBR)
기간: Up to 1 year 6 months

CBR is defined as the percentage of participants achieving CR or PR, or durable standard deviation (SD) of a duration of at least 11 weeks as defined by RECIST version 1.1.

Up to 1 year 6 months
All Cohorts Except Cohort 4: Progression-free Survival (PFS)
기간: Up to 3 years

The PFS is defined as the time from the first dose of study treatment until the date of objective disease progression or death, whichever comes first, based on RECIST version 1.1.

Up to 3 years
All Cohorts Except Cohort 4: Overall Survival (OS)
기간: Up to approximately 4 years

The OS is defined as the time from the first dose of study treatment until the date of death due to any cause.

Up to approximately 4 years
All Cohorts Except Cohort 4: Number of Participants with Venous Thromboembolic Events (VTE)
기간: Up to 1 year 6 months

Number of participants with adverse events of VTE (pulmonary embolism and deep vein thrombosis) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.

Up to 1 year 6 months
All Cohorts Except Cohort 4: Number of Participants with Venous Thromboembolic Events (VTE) by Severity
기간: Up to 1 year 6 months

Number of participants with adverse events of VTE (pulmonary embolism and deep vein thrombosis) by severity will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death).

Up to 1 year 6 months
All Cohorts Except Cohort 4: Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough) of Amivantamab
기간: Cycle 2 Day 1 of 28-day cycle

Ctrough is defined as the serum concentration of amivantamab immediately prior to the next drug administration.

Cycle 2 Day 1 of 28-day cycle
Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Intravenous (TASQ-IV)
기간: Up to 1 year 6 months

Patient-reported outcome (PRO): Cancer therapy satisfaction will be assessed using the modified TASQ-IV. The modified TASQ is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best.

Up to 1 year 6 months
Cohort 4: Cancer Therapy Satisfaction as Assessed by Modified Therapy Administration Satisfaction Questionnaire - Subcutaneous (TASQ-SC)
기간: Up to 1 year 6 months

PRO: Cancer therapy satisfaction will be assessed using the modified TASQ-SC. The modified TASQ is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best.

Up to 1 year 6 months
Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Change (PGIC) Scale Score
기간: Up to 1 year 6 months

Patient-reported status as assessed by PGIC scale score will be reported. The PGIC is an assessment of the participant's overall sense of whether there has been a change since starting treatment. The PGIC is a 7-point response scale. Participants will be asked to rate their current fatigue as compared to when they started the study, using the following 7-point scale: 1 = Much better, 2 = Moderately better, 3 = A little better, 4 = No change, 5 = A little worse, 6 = Moderately worse, and 7 = Much worse.

Up to 1 year 6 months
Cohort 4: Patient-reported Status as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score
기간: Up to 1 year 6 months

Patient-reported status as assessed by PGIS scale score will be reported. The PGIS is an assessment of lung cancer severity at a given point in time. The PGIS is a 5-point response scale. Participants will be asked to rate their fatigue over the past 7 days using the following 5-point scale: 1 = None, 2 = Mild, 3 = Moderate, 4 = Severe, and 5 = Very severe.

Up to 1 year 6 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2022년 11월 11일

기본 완료 (추정된)

2027년 8월 17일

연구 완료 (추정된)

2028년 8월 18일

연구 등록 날짜

최초 제출

2022년 8월 10일

QC 기준을 충족하는 최초 제출

2022년 8월 10일

처음 게시됨 (실제)

2022년 8월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다